ANP.AX - Antisense Therapeutics Limited
| Previous close | 0.0600 |
| Open | 0.0650 |
| Bid | 0.0600 x 50000000 |
| Ask | 0.0640 x 34112000 |
| Day's range | 0.0610 - 0.0650 |
| 52-week range | 0.0600 - 0.1500 |
| Volume | |
| Avg. volume | 433,554 |
| Market cap | 42.836M |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 29 Aug 2023 - 04 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireLong COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targetsProvisional patent applications have been filed in the United States (US) to seek protection for these new inventionsA potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19Collabo
- Simply Wall St.
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
GlobeNewswireNew Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
Figure 1 Quad RNA ddPCR (Pooled) Figure 2 Quad RNA ddPCR (Female) LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in the USStudy results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscleData supports progression into a longer-term efficacy study planned for 3Q/4Q2022 Mark Diamond, Antisense Therapeutics Mana